Pharmac is often criticised for not funding enough new medicines and for being too slow to determine which ones it will fund. However, being slow and focused is not proof of being too slow or too focused. Newish evidence from Germany reinforces this point.
Policy Point: Pharmac should not be criticised simply for being selective and slow about the medicines it funds
Dr Bryce Wilkinson
3 August, 2023
Contact persons
Dr Bryce Wilkinson
Senior Fellow